Xenon Pharmaceuticals Inc. | Mid-cap | Healthcare

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -279.3M
Net Income -234.3M

Balance Sheet Metrics

Total Assets 798.1M
Total Liabilities 43.2M
Shareholders Equity 754.9M
Debt to Equity 0.06

Cash Flow Metrics

Operating Cash Flow -190.5M
Free Cash Flow -184.5M

Revenue & Profitability Trend

Xenon Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue009.4M18.4M32.2M
Cost of Goods Sold-----
Gross Profit-----
Operating Expenses279.3M214.1M138.6M97.4M63.5M
Operating Income-279.3M-214.1M-129.1M-79.0M-31.3M
Pre-tax Income-238.4M-182.7M-125.3M-78.9M-29.1M
Income Tax-4.1M-292.0K118.0K-6.0K-257.0K
Net Income-234.3M-182.4M-125.4M-78.9M-28.8M
EPS (Diluted)--$2.73-$2.06-$1.77-$0.81

Income Statement Trend

Xenon Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets635.3M645.0M600.3M559.0M181.8M
Non-Current Assets162.9M319.8M153.8M13.0M7.4M
Total Assets798.1M964.8M754.1M572.0M189.2M
Liabilities
Current Liabilities35.6M27.3M22.7M14.3M14.8M
Non-Current Liabilities7.6M9.6M9.9M7.7M3.0M
Total Liabilities43.2M36.9M32.6M22.0M17.8M
Equity
Total Shareholders Equity754.9M927.9M721.5M550.0M171.4M

Balance Sheet Composition

Xenon Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-234.3M-182.4M-125.4M-78.9M-28.8M
Operating Cash Flow-190.5M-146.6M-101.7M-72.0M-50.4M
Investing Activities
Capital Expenditures-3.1M-5.6M-2.9M-2.0M-2.6M
Investing Cash Flow165.0M-117.2M-296.0M-246.8M-16.8M
Financing Activities
Dividends Paid-----
Financing Cash Flow12.1M353.5M277.8M447.3M85.7M
Free Cash Flow-184.5M-150.9M-101.3M-71.6M-50.8M

Cash Flow Trend

Xenon Key Financial Ratios

Valuation Ratios

Forward P/E -8.95
Price to Book 3.47
Price to Sales 326.07
PEG Ratio -8.95

Profitability Ratios

Profit Margin 0.00%
Operating Margin -969.84%
Return on Equity -31.60%
Return on Assets -22.03%

Financial Health

Current Ratio 17.66
Debt to Equity 1.23
Beta 1.10

Per Share Data

EPS (TTM) -$3.22
Book Value per Share $9.19
Revenue per Share $0.10

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
xene2.4B-3.47-31.60%0.00%1.23
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.1424.23-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.